Psoriasis Trial, Recruiting (NCT07615712)

Psoriasis Trial, Recruiting NCT07615712 Sponsor: CorEvitas Condition: Psoriasis

Printed from Voxsanity (voxsanity.com.au) — NCT07615712 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Psoriasis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are at least 18 years old at the time of joining the study
People who have been assessed by their doctor as having moderate to severe plaque psoriasis, based on a standard clinical assessment score of 3 or 4
People who are starting a new qualifying medication for plaque psoriasis for the first time
People who are willing and able to give their consent to take part in the study
People who are able to attend in-person appointments with their dermatology provider at 2, 4, and 16 weeks after starting the new treatment

Who may not be able to join:

People who are currently taking part in a blinded clinical trial (a type of study where participants do not know which treatment they are receiving)
People who do not receive at least one dose of the qualifying treatment within 14 days of their initial study enrollment visit
People who are currently enrolled in the CorEvitas PSO Registry, as enrollment in both the CorEvitas PSO Registry and this study at the same time is not permitted (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +1 508 408 5433

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07615712

Sponsor: CorEvitas

Phase: Not Applicable

Status: Recruiting

Condition: Psoriasis

Trial contact: +1 508 408 5433

More information: https://clinicaltrials.gov/study/NCT07615712

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are at least 18 years old at the time of joining the study
People who have been assessed by their doctor as having moderate to severe plaque psoriasis, based on a standard clinical assessment score of 3 or 4
People who are starting a new qualifying medication for plaque psoriasis for the first time
People who are willing and able to give their consent to take part in the study
People who are able to attend in-person appointments with their dermatology provider at 2, 4, and 16 weeks after starting the new treatment

Who may not be able to join:

People who are currently taking part in a blinded clinical trial (a type of study where participants do not know which treatment they are receiving)
People who do not receive at least one dose of the qualifying treatment within 14 days of their initial study enrollment visit
People who are currently enrolled in the CorEvitas PSO Registry, as enrollment in both the CorEvitas PSO Registry and this study at the same time is not permitted (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

CorEvitas

Registry

ClinicalTrials.gov

Start date

30 April 2025

Est. completion

1 December 2035

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Creation of a cohort of psoriasis subjects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov